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Emerging evidence suggests that short sleep is associated with an increased risk of cancer; however, little has been done to study
the role of sleep on tumor characteristics. In this study, we evaluated the relationship between sleep duration and tumor phenotype
in 972 breast cancer patients. Sleep duration was inversely associated with tumor grade (univariate 𝑃 = 0.032), particularly in
postmenopausal women (univariate 𝑃 = 0.018). This association did not reach statistical significance after adjustments for age,
race, body mass index, hormone replacement therapy use, alcohol consumption, smoking, and physical activity in the entire study
sample (𝑃 = 0.052), but it remained statistically significant (𝑃 = 0.049) among post-menopausal patients. We did not observe a
statistically significant association between sleep duration and stage at diagnosis, ER, or HER2 receptor status.These results present
a modest association between short duration of sleep and higher grade breast cancer in post-menopausal women. Further work
needs to be done to validate these findings.
1. Introduction
Breast cancer is the leading cancer in women in the United
States and the third leading cause of cancer deaths among
women [1]. It was estimated that over 220,000 women will
be diagnosed in 2012 with breast cancer, with almost 40,000
women deaths [2]. Women diagnosed with localized breast
cancer have a very favorable outcome, with a 99% 5-year
survival. However, the survival rate decreases to 84% with
regional disease and 23% for women with distant metastases,
underscoring the importance of identifying factors associated
with the development of more aggressive breast cancers.
There is an emerging evidence for the role of sleep
deprivation in carcinogenesis, with new research suggesting
that disruptions in the circadian rhythm may increase the
risk of several types of cancer [3–5], including breast cancer
(reviewed in [6]). In the few studies of sleep duration and
risk of breast cancer, the association of short sleep duration
and the incidence of breast cancer has been mixed, with one
study suggesting a decreased risk of breast cancer in women
who slept longer [7], two other studies showing an inverse
association between sleep duration and risk of breast cancer
[8, 9], and a fourth study that did not find evidence of this
association [10].
However, much less work has been done to investi-
gate whether short sleep duration prior to the diagnosis is
associated with breast cancer phenotype. Markers of more
aggressive and advanced breast cancer include stage, deter-
mined by the size of the tumor and lymph node status or
distant metastases, tumor grade, hormone receptor status,
and HER2 expression status. Patients with HER2 positive
and/or estrogen receptor (ER) negative breast cancer carry
a poorer prognosis with a higher risk of recurrence [11]. For
patients with hormone receptor-positive early breast cancer
(stage I or II), OncotypeDX, a gene-expression-basedmarker
of increased likelihood of cancer recurrence, has been used
to help guide the clinical decisions regarding the benefit of
chemotherapy [12]. Oncotype DX recurrence scores correlate
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with higher tumor grade and lower estrogen receptor expres-
sion [13, 14]. We recently reported the association of short
sleep duration with higher Oncotype DX recurrence scores
among post-menopausal breast cancer patients [15].
The aim of this study was to further explore the rela-
tionship between sleep deprivation and markers of cancer
aggressiveness in breast cancer patients. We examined the
association of sleep duration with the stage and grade of
tumor as well as tumor markers (ER and HER2 expression).
We further stratify by menopausal status, as we hypothesize
that the sleep duration would have a disproportionate effect
on post-menopausal breast cancer patients, in light of our
earlier findings [15].
2. Materials and Methods
2.1. Patient Population. The longitudinal changes inmammo-
graphic density and risk of breast cancer study is an ongoing
breast cancer case-control study of women with multiple
screening mammograms. Women with newly diagnosed
breast cancer (including DCIS) at the University Hospitals
CaseMedical Center (UHCMC), as well as controls recruited
at the time of screening mammography, were approached
for recruitment for study participation from January 2007
through July 2012. Exclusion criteria included prior non-
surgical treatment for any cancer, other concurrent cancers,
or known presence of BRCA1 or BRCA2 mutation. Patients
must speak English to be eligible for participation. Only
the breast cancer patients were included in this study. All
participants completed a phone survey based on a validated
questionnaire developed and used by the researchers at the
University of Southern California for breast cancer research
[16]. Participants also donated a blood sample for genetic and
biomarker studies and consented to link their study data to
theirmedical records.All patients provided informed consent
linking their responses to their medical record data, and
the study was approved by the UHCMC institutional review
board.
2.2.DataCollection. Patients enrolled in the studywere asked
by phone survey about their average length of sleep at night
for the 2 years prior to the diagnosis as well as additional
lifestyle and demographic factors. Body mass index (BMI)
was calculated from self-reported height and weight prior to
diagnosis. Physical activity was coded as the sum of the self-
reported average weekly hours of strenuous and moderately
strenuous physical activity. Smoking was defined as current
smoker versus noncurrent smoker, which includes both never
smokers and past smokers. Alcohol consumption was based
on questions about the average weekly number of drinks of
beer or ciders, wine and hard liquor, or mixed drinks in the
two years prior to diagnosis. Current drinkers were coded as
those individuals reporting drinking at least one drink per
week. Menopausal status was defined as post-menopausal for
women self-reporting having no menstrual periods within
the previous 6 months, including women who have not had
a menstrual period due to surgery, and premenopausal for
those reporting a recent menstrual period. Race was self-
reported as Caucasian, African-American, Hispanic, Asian,
or Other. Due to small numbers, Hispanic and Asian par-
ticipants were coded as “Other.” Current use of hormone
replacement therapy (HRT) was defined as self-reported use
of estrogen and/or progesterone replacement therapy for one
month or longer any time during the two years prior to
diagnosis (cases) or two years prior to recruitment (controls).
Medical records were obtained and reviewed for tumor
stage at diagnosis, modified Bloom-Richardson grade, and
hormone receptor and HER2 status (when available). When
therewere concurrent tumors present, themost advanced one
was coded.
2.3. Statistical Analysis. Sleep was treated as a continuous
variable and categorized into less than 6 hours per night,
at least 6 but less than 7 hours per night, and at least 7
hours per night, as we previously found it to be associated
with Oncotype DX score (15). The statistical significance
of differences in demographic and clinical characteristics
among the women in the three sleep categories was done
using a chi-square test (for categorical variables), or a one-
way analysis of variance (ANOVA) (for continuous variables).
Mean hours of sleep per night was calculated for each tumor
characteristic, and the statistical significance of differences
in means was calculated using ANOVA. In order to assess
the univariate trend of increasing stage and grade with hours
of sleep, we used an ordinal logistic regression with sleep
duration as a continuous variable.
Average sleep duration is known to vary with age, obesity,
and other lifestyle variables. In order to adjust for these
potential confounders, we tested the association of self-
reported average hours of sleep per night with grade, stage,
ER status, and HER2 status using logistic regression models
(ordinal logistic regression for grade and stage). In each
regression model, we adjusted for age, race, HRT, BMI,
current smoking, current alcohol consumption, and physical
activity, as all these factors are known to be associated with
sleep duration.
In light of our earlier findings that the association of
Oncotype DX score and sleep duration was limited to post-
menopausal patients, and the known difference in etiologies
of pre- and post-menopausal breast cancer, we then repeated
all statistical analyses stratified by menopausal status. All
statistics were performed using SAS v.9.2, using 𝑃 values <
0.05 for significance.
3. Results
From a total of 1,097 breast cancer patients participating
in the study, we were unable to locate medical records for
118 patients. Two patients were excluded from this analysis
due to diagnoses of Paget’s disease or Phyllodes tumor. Five
additional patients with missing sleep duration data were
excluded. The remaining 972 patients were included in the
study.
Table 1 shows the characteristics of the study population
overall and by category of sleep duration. There was a
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Table 1: Patient characteristics by category of average hours of sleep.
All
(𝑁 = 972)
Less than 6 hours of
sleep/night
(𝑁 = 105)
6 to less than 7 hours
of sleep/night
(𝑁 = 223)
7 or more hours of
sleep per night
(𝑁 = 644)
𝑃
∗
Age, mean (SD) 58.0 (11.4) 57.8 (11.0) 57.3 (11.1) 58.4 (11.6) 0.44
Postmenopausal,𝑁 (%) 0.87
Yes 817 (84.1%) 88 (10.8%) 190 (23.3%) 539 (66.0%)
No 155 (16.0%) 17 (11.0%) 33 (21.3%) 105 (67.7%)
Race,𝑁 (%) <0.0001
Caucasian 831 (85.5%) 74 (70.5%) 183 (82.1%) 574 (89.1%)
African American 126 (13.0%) 28 (26.7%) 37 (16.6%) 61 (9.5%)
Other 15 (1.5%) 3 (2.9%) 3 (1.4%) 9 (1.4%)
Body mass index, kg/m2, mean
(SD) 28.1 (6.5) 29.4 (7.1) 28.7 (7.3) 27.7 (6.1) 0.015
Physical activity per week, hours,
mean (SD) 4.0 (4.1) 3.6 (4.6) 4.1 (4.3) 4.0 (3.9) 0.55
Current alcohol use,𝑁 (%) <0.0001
Yes 473 (48.7%) 30 (71.4%) 91 (40.8%) 352 (54.7%)
No 499 (51.3%) 75 (28.6%) 132 (59.2%) 292 (45.3%)
Current HRT user,𝑁 (%) 0.63
Yes 143 (14.7%) 16 (15.2%) 37 (16.6%) 90 (14.0%)
No 829 (85.3%) 89 (84.8%) 186 (83.4%) 554 (86.0%)
Stage,𝑁 (%) 0.30
0 (DCIS) 199 (20.5%) 24 (22.9%) 46 (20.6%) 129 (20.0%)
1 395 (40.6%) 37 (35.2%) 79 (35.4%) 279 (43.3%)
2 278 (28.6%) 31 (29.5%) 68 (30.5%) 179 (27.8%)
3 62 (6.4%) 8 (7.6%) 21 (9.4%) 33 (5.1%)
4 21 (2.2%) 3 (2.9%) 5 (2.2%) 13 (2.0%)
Missing 17 (1.7%) 2 (1.9%) 4 (1.8%) 11 (1.7%)
Grade,𝑁 (%) 0.40
1 145 (14.9%) 10 (9.5%) 30 (13.5%) 105 (16.3%)
2 309 (31.8%) 35 (33.3%) 68 (30.4%) 206 (32.0%)
3 209 (21.5%) 23 (21.9%) 53 (23.8%) 133 (20.7%)
Missing 309 (31.8%) 37 (35.2%) 72 (32.3%) 200 (31.1%)
ER status 0.0064
Positive 734 (75.5%) 83 (79.0%) 155 (69.5%) 496 (77.0%)
Negative 173 (17.8%) 15 (14.3%) 56 (25.1%) 105 (16.3%)
Unknown/not done/missing 65 (6.7%) 7 (6.7%) 12 (5.4%) 46 (7.1%)
HER2 status 0.38
Positive 135 (13.9%) 17 (16.2%) 34 (15.2%) 84 (13.0%)
Negative 599 (61.6%) 57 (54.3%) 135 (60.5%) 407 (63.2%)
Unknown/not done/missing 238 (24.5%) 31 (29.5%) 54 (24.2%) 153 (23.8%)
∗
𝑃 value of ANOVA (for continuous variables) or chi-square (for categorical variables) test; HRT: hormone replacement therapy.
significant difference in sleep duration by race, as African
American women reported less sleep than Caucasian women
(𝑃 < 0.0001). As expected, women who reported fewer hours
of sleep had higher BMI (𝑃 = 0.015). We also noted that
short sleepers were less likely to be current alcohol drinkers
(𝑃 < 0.0001). No clear trend was observed for menopausal
status, stage, grade, estrogen receptor status, or HER2 status
with sleep duration category.
Table 2 compares the differences in mean self-reported
average hours of sleep per night with different measures of
an aggressive breast cancer phenotype. In univariate analyses,
a significant inverse relationship was found between sleep
category duration and grade, with women with higher grade
tumors reporting less sleep prior to diagnosis (𝑃 = 0.032,
Table 2), as well as sleep as a continuous variable and
tumor grade (𝑃 = 0.011). This association was found in
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Table 2: Mean self-reported average hours of sleep per night by patient characteristic.
All patients Premenopausal Postmenopausal
Hours of sleep per
night, mean (SD) 𝑃
∗
𝑃
∗∗ Hours of sleep per
night, mean (SD) 𝑃
∗
𝑃
∗∗ Hours of sleep per
night, mean (SD) 𝑃
∗
𝑃
∗∗
All 7.03 (1.20) N/A N/A 7.08 (1.24) N/A N/A 7.02 (1.20) N/A N/A
Stage 0.031 0.36 0.40 0.60 0.026 0.26
0 (DCIS) 6.98 (1.20) 7.11 (0.85) 6.95 (1.28)
1 7.14 (1.20) 7.07 (1.42) 7.15 (1.16)
2 6.99 (1.16) 7.23 (1.28) 6.94 (1.13)
3 6.65 (1.14) 6.42 (1.17) 6.67 (1.14)
4 7.12 (1.68) 6.00 (1.41) 7.24 (1.69)
Grade 0.032 0.052 0.022 0.89 0.018 0.049
1 7.23 (1.20) 7.63 (1.34) 7.16 (1.17)
2 7.05 (1.24) 6.75 (1.27) 7.11 (1.23)
3 6.89 (1.18) 7.27 (1.38) 6.82 (1.13)
ER status 0.31 0.71 0.38 0.88 0.47 0.69
Positive 7.04 (1.21) 7.10 (1.30) 7.03 (1.19)
Negative 6.94 (1.19) 6.88 (0.98) 6.95 (1.23)
HER2 status 0.17 0.23 0.79 0.64 0.17 0.31
Positive 6.91 (1.10) 7.00 (0.89) 6.89 (1.13)
Negative 7.06 (1.21) 7.09 (1.43) 7.06 (1.18)
∗
𝑃 value of ANOVA (univariate); ∗∗𝑃 value of sleep duration in ordinal or standard logistic regression adjusted for age, race, hormone replacement therapy
(HRT), family history of breast cancer, body mass index (BMI), current smoking, current alcohol consumption, and physical activity.
post-menopausal women (sleep categories 𝑃 = 0.018, sleep
hours as continuous 𝑃 = 0.010), but no trend was observed
in pre-menopausal women (sleep categories 𝑃 = 0.022, sleep
hours as continuous 𝑃 = 0.59). There was no univariate
correlation between hours of sleep per night and stage (𝑃 =
0.22). Although, as hypothesized, womenwith positiveHER2
status reported fewer hours of sleep on average, it was not
statistically significant (ANOVA 𝑃 = 0.17).
In multivariate analyses adjusting for age, race, BMI,
physical activity, current HRT use, tobacco, and alcohol
use, average hours of sleep per night no longer remained
statistically significantly associated with grade (𝑃 = 0.052).
However, the statistical significance of this association among
post-menopausal breast cancer patients remained (𝑃 =
0.049). As expected, after adjustment, no association among
premenopausal breast cancer patients was observed (𝑃 =
0.46).
4. Discussion
According to the National Sleep Foundation (NSF), a healthy
adult should sleep 7–9 hours/day [17]. A survey conducted by
the National Health Interview Survey (NHIS) revealed that
about 30% of employed US civilian adults report an average
sleep duration of ≤6 hours a day, which highlights lack of
sufficient sleep as a public health problem [18]. Previous
studies suggest that sleep deprivation is a risk factor for the
development of breast cancer [8, 9]. We recently showed that
short sleep duration correlates with higher Oncotype DX
recurrence scores in post-menopausal breast cancer patients
[15]. In this study, we show a modest association between
short sleep duration and higher grade of breast cancer, which
is limited to post-menopausal women.
Multiple studies have reported an association between
short sleep duration and the risk of developing cancer. The
biologic basis for this association has yet to be determined.
The metabolic syndrome describes the clustering of hyper-
tension, dyslipidemia, obesity, and insulin-resistance [19].
Sleep deprivation is linked with obesity and the metabolic
syndrome [20, 21], both of which contribute to breast
cancer incidence and stage at presentation, although our
multivariate analysis accounted for BMI differences. Turek
et al. reported in their animal trial that mice homozygous
for a mutant Clock gene, a gene that influences both the
persistence and periods of circadian rhythms, tend to have a
higher food intake, were obese and more prone to develop
metabolic syndrome with high levels of leptin, lipids, glu-
cose and reduced compensatory insulin production [22].
Insulin resistance has been shown to be a risk factor for
the incidence of breast cancer, again primarily in post-
menopausal women, and negatively impacts prognosis [23,
24]. Although insulin resistance is correlated with BMI, we
did not specifically adjust for independent effects of insulin
resistance. Sleep deprivation also has a proinflammatory and
immuno-modulatory effect, which may contribute to the
development of more aggressive cancers [25].
It has been observed that genes regulating the sleep cycle
are deregulated in cancers [26]. Two sleep-related genes,
PERIOD1 and PERIOD3, which are key regulators of our
circadian rhythm, have been found to affect the apoptosis
in cancer cell lines [27]. A recent study, which used a
combination of human breast tumor analysis and mouse
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models, further showed that a deletion/reduced expression
of PERIOD3 gene on chromosome 1p36 was related to the
recurrence of the tumor in ER + breast cancer patients,
further highlighting the role of the circadian rhythm in tumor
aggressiveness [28].
Another possible explanation may be found in the role
of melatonin in the regulation of the circadian rhythm
and its potential effects on the breast cancer. Melatonin
depletion has been seen in breast cancer patients, with
low nighttime peaks [29], rather than low daily levels [30],
correlating with advanced stage at presentation. Antineo-
plastic properties of melatonin in preclinical models include
antioxidant, proapoptotic, antiinflammatory, antiangiogenic,
immunostimulatory effects, and alterations in metabolism
and gene regulation [31]. It is now well known that the
constant exposure to light at night promotes tumorigenesis by
inhibiting nocturnal release of melatonin by the pineal gland.
It was initially highlighted in an experimental model where
either the surgical removal of pineal gland or constant light
promoted mammary tumorigenesis in rodents [32]. These
findings were further strengthened by the work of Blask
et al. [33]. In this study, blood samples were taken from
healthy, premenopausal women either in daytime, nighttime,
or nighttime after the exposure to bright, white fluorescent
light. These blood samples were then perfused in the human
breast cancer xenografts in nude rats. It was noted that
the nighttime samples with physiological melatonin-rich
levels significantly suppressed the tumor proliferative activ-
ity and linoleic acid metabolism. However, the melatonin
deficient samples following ocular light exposure simulated
the increased tumor proliferative activity of the daytime
samples.Moreover, this relationshipwas found to be intensity
dependent [33]. In addition, using a tissue isolated human
breast xenograft tumor nude ratmodel,Mao et al. highlighted
the link between melatonin and glycogen synthase kinase 3𝛽
(GSK3𝛽), an enzyme that plays a vital role in metabolism
and cell proliferation. Melatonin is responsible for activating
GSK3𝛽, which in turn inhibits epithelial-to-mesenchymal
transition, a critical process in underlying cancer spread
and metastasis. The exposure to light at night was found
to suppress the nocturnal pineal gland melatonin synthesis
leading to the inhibition of circadian phosphorylation of
GSK3𝛽 and hence increasing the susceptibility to breast
cancer spread [34]. Furthermore, melatonin has multiple
antiestrogenic effects, acting to decrease ovarian estrogen
production, reducing aromatase activity, and decreasing ER-
𝛼 expression and estrogenmediated transcription of prolifer-
ative genes [35].
Due predominantly to the large number of DCIS (stage
0) patients in our sample, for which HER2 is not routinely
tested, HER2 status was not available for a large proportion
of our study population (24.5%). In our sample, patients
with HER2 positive breast cancer reported less average
nightly sleep. Although this association was not statistically
significant, we feel it is worth following up in a larger
sample population. There was no clear association between
sleep duration and the development of metastatic breast
cancer, as premenopausal patients with stage IV disease slept
less, whereas post-menopausal patients with stage IV disease
slept more, although our sample size in this group was very
small.
There are additional limitations in our study. First, the
self-reported duration of sleep is subject to recall bias and
does notmeasure other parameters of sleep, including quality
and sleep patterns, which may also be important risk factors
for breast cancer aggressiveness, but we are unable to study
in this sample. However, given that we recruited patients at
diagnosis, we feel that this recall bias would be minimal.
In addition, we only queried on sleep duration for the two
years prior to diagnosis. We cannot address possible effects
of sleep earlier in life or the longer term effects of short sleep
duration. Secondly, although our study population reflects
the racial distribution of the patients seen at this hospital,
a majority of our study population is Caucasian. Further
work will need to be done in other populations with more
minorities to assess generalizability of our findings. A large
study population added to the strength of the study; however,
the small number of premenopausal patients limits our ability
to make conclusions in that subset of patients. However,
the observed effect of the association of sleep with grade in
the premenopausal population is much smaller than that in
the post-menopausal group. Therefore, while we cannot rule
out an effect of sleep duration with grade in premenopausal
women, our data suggests that if such an effect exists, it is
likely to be a smaller effect than in post-menopausal breast
cancer patients.
To the best of our knowledge, this is only the second study
to investigate the association between sleep duration and
breast cancer phenotype, the first being our study on sleep
duration and Oncotype DX score. Approximately 1 in 8 US
women will develop breast cancer in their lifetime. With the
additional mortality and costs associated with treating more
aggressive breast cancers, it is important to understand that
risk factors that affect breast cancer severity. Given that 30%
of adults sleep less than 6 hours per night [18], the association
of short sleep duration with breast cancer incidence and
phenotype suggests that the attributable population risk due
to short sleep duration is high. Further studies are required
to validate these findings, as well as to identify the biological
reasons for this observed association.
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